About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Aug 27, 2021... ImmunoBrain Checkpoint Inc. (“IBC”) an innovative biopharmaceutical company developing potential disease-modifying immune therapies that harness the power of the immune system to help protect and repair the brain to combat neurodegenerative diseases, announced today that the National Institute on Aging (NIA) of the US National Institutes of Health (NIH) has awarded the Company a grant totaling $5 million over three years to support a first-in-human clinical study of IBC-Ab002, for the treatment of Alzheimer’s disease.
©2022 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR